Suven Life Sciences Q3 net down 45% at Rs 17.71 cr

Image
Press Trust of India New Delhi
Last Updated : Feb 12 2016 | 6:22 PM IST
Drug firm Suven Life Sciences today reported a 45 per cent dip in standalone net profit to Rs 17.71 crore for the third quarter ended December 31, 2015.
The company had posted a net profit of Rs 32.22 crore in the corresponding period of the previous fiscal, Suven Life Sciences said in a filing to BSE.
Standalone net sales of the company stood at Rs 112.50 crore for the quarter under review. It was Rs 128.82 crore for the same period a year ago.
Shares of Suven Life Sciences today closed at Rs 175.35 per scrip on BSE, down 9.05 per cent from the previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 12 2016 | 6:22 PM IST

Next Story